Downloads

31. Boost Flexibility And Time To Market With Modular Production 4/29/2026

    Learn how organizations are applying digital technologies with purpose, not guesswork. Real-world use cases highlight modular design, connected workers, and predictive maintenance.

32. Be Smart: Flexible Production With Module Type Package (MTP) 4/29/2026

    Modular production is moving from vision to practice. Learn how the Module Type Package enables flexible manufacturing while unlocking valuable process data based on real implementation experience.

33. From Molecule To Market: Proven Solutions From R&D To Manufacturing 4/29/2026

    Gain insight into a connected approach to pharmaceutical development that links R&D, manufacturing, and supply chain operations to improve visibility, speed, and quality.

34. Standardized Extraction Protocol Per USP <665>: Bridging Regulatory Expectations And Industry Best Practices 4/29/2026

    View how to implement USP <665> extractables testing, align with global E&L standards, and apply risk-based strategies to ensure regulatory compliance and patient safety.

35. Minimizing Regulatory Risk For Biologics Manufacturing Changes 4/29/2026

    Any manufacturing process change for a biologic can raise comparability questions. Here’s a practical, action-oriented strategy to ensure health authorities are satisfied.

36. Simplifying Cell Harvest with Single-Use Centrifuge Bags 4/28/2026

    Optimize small-scale cell harvest with sterile, single-use bioprocess bags. High-performance film and a closed-system design ensure process integrity while reducing contamination risks.

37. Next-Gen Modalities, Expertly Enabled 4/27/2026

    Integrated oligo, peptide, and conjugate capabilities support novel modalities from discovery through GMP with scalable synthesis and advanced analytics.

38. Using Tech Transfer To Accelerate NDA Approval 4/27/2026

    A biotech company accelerated NDA approval for a novel anti‑infective by executing a highly disciplined, first‑time‑right technology transfer and registration batch manufacturing strategy.

39. From DNA To IND In As Little As 6 Months 4/27/2026

    Discover how an integrated, platform-driven CMC approach can accelerate your antibody program from DNA to IND in as little as six months while reducing risk and maintaining quality and regulatory alignment.

40. Scale GMP Operations Across Sites 4/27/2026

    Blue Mountain Regulatory Asset Manager (RAM) helps life sciences manufacturers standardize maintenance, calibration, and asset workflows across sites in one validated platform.